Form 4: Esperion Therapeutics CEO Acquires 840,000 Shares and 753,000 Stock Options
SEC Form 4 Filing
Esperion Therapeutics CEO, Sheldon L. Koenig, reports acquisition of 840,000 common stock shares and 753,000 stock options on March 14, 2025.
Summary
- On March 14, 2025, Sheldon L. Koenig, the President and CEO of Esperion Therapeutics, Inc., acquired 840,000 shares of common stock.
- Koenig also acquired 753,000 stock options with an exercise price of $1.50.
- The stock options vest over a four-year period in equal quarterly installments, starting on June 15, 2025.
- Following the reported transactions, Koenig beneficially owns 1,585,009 shares of common stock and 753,000 stock options.
- This includes 5,190 shares recently acquired in Esperion's Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO increasing their stake in the company is generally a good sign, but it's a routine transaction.
Positives
- The CEO's acquisition of a significant number of shares and options could be interpreted as a positive signal about the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Stakeholder Impact
- The CEO's increased stake could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 03/17/2025 | Date of signature on the Form 4 filing. |
| 06/15/2025 | First vesting date for the acquired stock options. |
| 03/14/2035 | Expiration date for the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.